Archives
-
DAPT (GSI-IX): From Notch Biology to Translation
2026-09-01
DAPT (GSI-IX) is a selective γ-secretase inhibitor that connects amyloid precursor protein processing with Notch-dependent cell-fate decisions. This thought-leadership guide shows how translational researchers can use DAPT to separate pathway causality from phenotype, interpret combination media studies responsibly, and build stronger Alzheimer’s disease research, cancer research, and regenerative medicine workflows.
-
SMYD2 Inhibition in Cisplatin-Induced Renal Fibrosis
2026-09-01
The reference study shows that pharmacological inhibition of SMYD2 with AZ505 or LLY507 reduces cisplatin-associated renal injury, fibrosis, epithelial-mesenchymal transition, and inflammation. Its main contribution is to connect SMYD2 activity with Smad3- and STAT3-related signaling, providing a testable epigenetic target for chronic kidney disease research.
-
Proteinase K for DNA and Candida EV Workflows
2026-08-31
Proteinase K combines broad protein digestion with compatibility across EDTA, detergents, and DNA-preserving workflows. This guide shows how to use it for genomic DNA isolation, enzyme contaminant removal, and protease-protection experiments inspired by Candida albicans extracellular-vesicle research.
-
SIS3 and the TGF-β/SMAD3 Circuit
2026-08-31
SIS3 is a selective Smad3 inhibitor for separating canonical TGF-β signaling from broader pathway effects. This article connects its assay utility to the super-enhancer–SMAD3 feedback circuit identified in lung adenocarcinoma and to fibrosis research applications.
-
Hematoxylin and Eosin Staining Kit: H&E Workflow
2026-08-30
The Hematoxylin and Eosin Staining Kit (SKU K1142) provides ready-to-use reagents for visualizing nuclei, cytoplasm, and extracellular tissue features in paraffin sections, frozen sections, and cytological preparations. It is intended for scientific research and morphology assessment only, not for diagnostic or medical use.
-
ONX-0914 and Hippocampal Synaptic Plasticity
2026-08-29
Maltsev and colleagues show that chronic inhibition of non-constitutive proteasomes with ONX-0914 selectively weakens tetanus-evoked, but not theta-burst-evoked, hippocampal long-term potentiation in mice. The study links this protocol-specific physiological effect to altered expression of genes involved in glutamatergic signaling and synaptic plasticity, refining how proteasome subtypes are understood in the CNS.
-
Masitinib (AB1010): KIT/PDGFR Workflow Guide
2026-08-28
Masitinib (AB1010) is a DMSO-compatible phenylaminothiazole-type tyrosine kinase inhibitor for selective KIT and PDGFRα/β pathway studies. It is suited to defined biochemical and cell-based assays, but not to aqueous or ethanol-based workflows, broad-spectrum kinase profiling, or direct clinical conclusions without independent evidence.
-
Gap19: Cx43 Hemichannel Selectivity in Translation
2026-08-28
Gap19 offers a mechanistically precise way to interrogate connexin 43 hemichannel biology while preserving gap junction communication. This thought-leadership analysis connects astrocytic ATP release, neuroprotection in cerebral ischemia, macrophage Cx43/NF-κB signaling, and JAK2/STAT3 pathway modulation to practical translational study design.
-
Endothelial SGK1 Drives Salt-Related Vascular Stiffening
2026-08-27
Zhang et al. show that endothelial SGK1 is a mechanistic link between mineralocorticoid and salt exposure and vascular stiffening. Genetic deletion and pharmacological inhibition reduced endothelial and aortic stiffness, with actin polymerization emerging as a key downstream process relevant to hypertension research.
-
ALDOB K87 Lactylation in Pulmonary Hypertension
2026-08-27
The reference study identifies ALDOB K87 lactylation as a metabolic–mitochondrial signaling node in pulmonary hypertension, linking hypoxia-driven lactate accumulation to DRP1-dependent mitochondrial fission and pulmonary artery smooth muscle cell remodeling. Its combination of lactylomic profiling, mechanistic perturbation, and rodent validation provides a framework for studying how post-translational metabolism controls vascular disease.
-
Angiotensin 1/2 (1-6) in Cell Assays
2026-08-26
Learn how Angiotensin 1/2 (1-6), SKU A1048, can support controlled cell viability, proliferation, cardiovascular, and renal research workflows. This scenario-based guide covers peptide identity, solvent compatibility, protocol optimization, interpretation of binding data, and practical vendor-selection criteria.
-
QRICH1–HMGB1 Signaling in HBV Fibrosis
2026-08-26
A 2025 Immunobiology study identifies QRICH1 as an endoplasmic reticulum stress effector that strengthens HBV-associated HMGB1 transcription, acetylation, translocation, and secretion. By combining a recombinant cccDNA mouse model with chronic hepatitis B specimens, the work connects ER stress signaling to inflammatory amplification and hepatic fibrosis while highlighting important limits on causal interpretation.
-
3-Hydroxybutyrate (BHBA): Design Better Assays
2026-08-25
3-hydroxybutyrate (BHBA) is more than a ketone fuel: it connects fatty acid oxidation, membrane biology, ferroptosis, and chromatin regulation. This article presents an assay-design framework for separating direct BHBA effects from whole-organism conditioning responses.
-
Gemcitabine HCl for MRI-Guided Tumor Studies
2026-08-25
Pair Gemcitabine HCl pharmacology with longitudinal MRI to connect DNA replication inhibition and apoptosis readouts with whole-tumor response. A multianimal workflow can improve cohort enrollment, treatment monitoring, and experimental efficiency in pancreatic cancer models.
-
EMD638683: From SGK1 Biology to Translation
2026-08-24
EMD638683 offers a practical way to interrogate SGK1-dependent sodium handling, endothelial stiffening, actin remodeling, NDRG1 phosphorylation, and tumor biology. This article connects mechanistic evidence with assay strategy and translational decision-making for cardiovascular and cancer researchers.